are you referring to mrx? what company would pay ~ 1 b (including acquisition premium) for a firm with one product in its bag that is facing fierce attacks by generics? if you don't believe me, wait until mrx cuts their next pay to delay check to mylan which will likely happen by 11/15 given the grandfather provision in the bill currently moving through the senate.

dysport is facing an economic head wind plus it is inferior to botox. restylane has seen its better days, is facing an economic head wind, and will continue to face new competition. lipsonix is a $150 million waste of money. the company should have taken the mentor deal years ago but they didn't given incompetent management and directors who are in management's pockets and enjoy lucrative annual paychecks. they only way they sell out now is if they find a buyer with a management team that is less savvy than mrx's management team and the chances of that happening are close to nil.